CN110049980A - 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法 - Google Patents
一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法 Download PDFInfo
- Publication number
- CN110049980A CN110049980A CN201880004976.2A CN201880004976A CN110049980A CN 110049980 A CN110049980 A CN 110049980A CN 201880004976 A CN201880004976 A CN 201880004976A CN 110049980 A CN110049980 A CN 110049980A
- Authority
- CN
- China
- Prior art keywords
- crystal
- solvent
- formula
- angle
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
涉及阿片样物质受体激动剂(1S,4S)‑4‑乙氧基‑N‑(2‑((R)‑9‑(吡啶‑2‑基)‑6‑氧杂螺[4.5]癸‑9‑基)乙基)‑1,2,3,4‑四氢萘‑1‑胺的富马酸盐、其富马酸盐I型晶型及其制备方法和用途。
Description
PCT国内申请,说明书已公开。
Claims (12)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017102421193 | 2017-04-14 | ||
CN201710242119 | 2017-04-14 | ||
PCT/CN2018/082935 WO2018188643A1 (zh) | 2017-04-14 | 2018-04-13 | 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110049980A true CN110049980A (zh) | 2019-07-23 |
CN110049980B CN110049980B (zh) | 2020-10-20 |
Family
ID=63792318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880004976.2A Active CN110049980B (zh) | 2017-04-14 | 2018-04-13 | 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法 |
Country Status (23)
Country | Link |
---|---|
US (2) | US11014914B2 (zh) |
EP (1) | EP3610875B1 (zh) |
JP (1) | JP7153030B6 (zh) |
KR (1) | KR20190140962A (zh) |
CN (1) | CN110049980B (zh) |
AU (1) | AU2018251119B2 (zh) |
BR (1) | BR112019021447A2 (zh) |
CA (1) | CA3057383A1 (zh) |
CY (1) | CY1124063T1 (zh) |
DK (1) | DK3610875T3 (zh) |
ES (1) | ES2828636T3 (zh) |
HR (1) | HRP20210022T1 (zh) |
HU (1) | HUE053244T2 (zh) |
LT (1) | LT3610875T (zh) |
MX (1) | MX2019012251A (zh) |
MY (1) | MY196571A (zh) |
PL (1) | PL3610875T3 (zh) |
PT (1) | PT3610875T (zh) |
RS (1) | RS61193B1 (zh) |
SI (1) | SI3610875T1 (zh) |
TW (1) | TWI682929B (zh) |
UA (1) | UA124400C2 (zh) |
WO (1) | WO2018188643A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109982699A (zh) * | 2017-04-14 | 2019-07-05 | 江苏恒瑞医药股份有限公司 | 一种mor激动剂与kor激动剂的药物组合物及其用途 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3610875B1 (en) * | 2017-04-14 | 2020-10-07 | Jiangsu Hengrui Medicine Co., Ltd. | Opioid receptor (mor) agonist salt, fumarate salt i crystal form thereof and preparation method thereof |
CN111836807A (zh) * | 2018-04-28 | 2020-10-27 | 四川科伦博泰生物医药股份有限公司 | 氧杂螺环类化合物及其制备方法和用途 |
WO2020073985A1 (zh) * | 2018-10-12 | 2020-04-16 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 |
WO2020073984A1 (zh) * | 2018-10-12 | 2020-04-16 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 |
CN111662284B (zh) * | 2019-03-06 | 2021-08-10 | 上海海雁医药科技有限公司 | 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途 |
KR20210113824A (ko) | 2020-03-09 | 2021-09-17 | 건국대학교 산학협력단 | 뮤 오피오이드 수용체의 활성화제를 유효성분으로 포함하는 기분 장애의 예방용 조성물 |
AU2022312049A1 (en) * | 2021-07-13 | 2024-02-22 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Pharmaceutically acceptable salt of mor receptor agonist, and polymorph thereof and use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103702561A (zh) * | 2011-03-23 | 2014-04-02 | 特维娜有限公司 | 阿片样物质受体配体以及使用和制备其的方法 |
WO2017063509A1 (zh) * | 2015-10-15 | 2017-04-20 | 江苏恒瑞医药股份有限公司 | 氧杂螺环类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3610875B1 (en) * | 2017-04-14 | 2020-10-07 | Jiangsu Hengrui Medicine Co., Ltd. | Opioid receptor (mor) agonist salt, fumarate salt i crystal form thereof and preparation method thereof |
-
2018
- 2018-04-13 EP EP18784878.3A patent/EP3610875B1/en active Active
- 2018-04-13 MX MX2019012251A patent/MX2019012251A/es unknown
- 2018-04-13 PL PL18784878T patent/PL3610875T3/pl unknown
- 2018-04-13 PT PT187848783T patent/PT3610875T/pt unknown
- 2018-04-13 UA UAA201911049A patent/UA124400C2/uk unknown
- 2018-04-13 BR BR112019021447A patent/BR112019021447A2/pt active Search and Examination
- 2018-04-13 US US16/499,453 patent/US11014914B2/en active Active
- 2018-04-13 RS RS20201514A patent/RS61193B1/sr unknown
- 2018-04-13 DK DK18784878.3T patent/DK3610875T3/da active
- 2018-04-13 SI SI201830176T patent/SI3610875T1/sl unknown
- 2018-04-13 ES ES18784878T patent/ES2828636T3/es active Active
- 2018-04-13 JP JP2019555801A patent/JP7153030B6/ja active Active
- 2018-04-13 AU AU2018251119A patent/AU2018251119B2/en active Active
- 2018-04-13 CA CA3057383A patent/CA3057383A1/en active Pending
- 2018-04-13 WO PCT/CN2018/082935 patent/WO2018188643A1/zh active Application Filing
- 2018-04-13 KR KR1020197033496A patent/KR20190140962A/ko active IP Right Grant
- 2018-04-13 TW TW107112721A patent/TWI682929B/zh active
- 2018-04-13 CN CN201880004976.2A patent/CN110049980B/zh active Active
- 2018-04-13 HU HUE18784878A patent/HUE053244T2/hu unknown
- 2018-04-13 LT LTEP18784878.3T patent/LT3610875T/lt unknown
-
2019
- 2019-10-03 MY MYPI2019005849A patent/MY196571A/en unknown
-
2020
- 2020-10-22 CY CY20201101000T patent/CY1124063T1/el unknown
-
2021
- 2021-01-07 HR HRP20210022TT patent/HRP20210022T1/hr unknown
- 2021-01-07 US US17/143,549 patent/US20210130332A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103702561A (zh) * | 2011-03-23 | 2014-04-02 | 特维娜有限公司 | 阿片样物质受体配体以及使用和制备其的方法 |
WO2017063509A1 (zh) * | 2015-10-15 | 2017-04-20 | 江苏恒瑞医药股份有限公司 | 氧杂螺环类衍生物、其制备方法及其在医药上的应用 |
Non-Patent Citations (2)
Title |
---|
SCOTT M. DEWIRE,等: "A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine", 《THE JOURNAL OF PHARMACOLOGY ANDE XPERIMENTAL THERAPEUTICS》 * |
XIAO-TAO CHEN,等: "Structure−Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R) ‑ 9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain", 《J. MED. CHEM.》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109982699A (zh) * | 2017-04-14 | 2019-07-05 | 江苏恒瑞医药股份有限公司 | 一种mor激动剂与kor激动剂的药物组合物及其用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2018188643A1 (zh) | 2018-10-18 |
US20200048229A1 (en) | 2020-02-13 |
US11014914B2 (en) | 2021-05-25 |
HUE053244T2 (hu) | 2021-06-28 |
BR112019021447A2 (pt) | 2020-05-05 |
AU2018251119B2 (en) | 2021-07-29 |
AU2018251119A1 (en) | 2019-11-07 |
TWI682929B (zh) | 2020-01-21 |
JP2020516642A (ja) | 2020-06-11 |
MY196571A (en) | 2023-04-19 |
JP7153030B6 (ja) | 2023-07-24 |
RS61193B1 (sr) | 2021-01-29 |
CA3057383A1 (en) | 2018-10-18 |
UA124400C2 (uk) | 2021-09-08 |
ES2828636T3 (es) | 2021-05-27 |
KR20190140962A (ko) | 2019-12-20 |
MX2019012251A (es) | 2019-11-28 |
CY1124063T1 (el) | 2022-03-24 |
RU2019136088A (ru) | 2021-05-14 |
LT3610875T (lt) | 2020-11-25 |
CN110049980B (zh) | 2020-10-20 |
JP7153030B2 (ja) | 2022-10-13 |
PT3610875T (pt) | 2020-11-25 |
US20210130332A1 (en) | 2021-05-06 |
SI3610875T1 (sl) | 2021-02-26 |
DK3610875T3 (da) | 2020-12-21 |
TW201837033A (zh) | 2018-10-16 |
EP3610875A1 (en) | 2020-02-19 |
RU2019136088A3 (zh) | 2021-06-16 |
PL3610875T3 (pl) | 2021-04-19 |
HRP20210022T1 (hr) | 2021-03-05 |
EP3610875A4 (en) | 2020-02-19 |
EP3610875B1 (en) | 2020-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110049980A (zh) | 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法 | |
CN108727347A (zh) | 一种阿片样物质受体(mor)激动剂的晶型及其制备方法 | |
CN109937200A (zh) | 一种苯并呋喃类衍生物游离碱的晶型及制备方法 | |
CN108778282A (zh) | 一种GnRH受体拮抗剂的结晶形式及其制备方法 | |
TW201815793A (zh) | 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法 | |
US10150739B2 (en) | Crystalline form of androgen receptor inhibitor and preparation method thereof | |
US8946474B2 (en) | Polymorphic form of a calcimimetic compound | |
CN112638906B (zh) | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 | |
CN112638907B (zh) | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 | |
US9056814B2 (en) | Polymorphic form of a calcimimetic compound | |
RU2779119C2 (ru) | Соль агониста опиоидного рецептора (mor), кристаллическая форма i его фумаратной соли и способ их получения | |
TW201904972A (zh) | 一種咪唑并異吲哚類衍生物游離鹼的晶型及其製備方法 | |
CN109963846A (zh) | 一种酪氨酸激酶抑制剂的二马来酸盐的晶型及其制备方法 | |
CN106946889A (zh) | 一种二肽基肽酶iv抑制剂的无定型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40011956 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |